Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sortilin-related receptor 1 (SORL1, also known as SORLA or LR11) is a large multidomain type I transmembrane sorting receptor predominantly expressed in the central nervous system[1]. SORL1 mediates endosomal recycling of membrane-bound proteins, including amyloid precursor protein (APP) and glutamate receptor subunit GluA1, thus regulating their cellular trafficking and processing[1][2][3]. It plays a key role in neuronal maintenance by guiding receptors and cargo from early endosomes to other cellular compartments via interaction with the retromer complex. Mutations in SORL1 confer high risk for Alzheimer's disease—similar to APP and presenilins—making it the fourth major causal gene for AD. Pathogenic variants disrupt its function, especially those affecting dimerization or interaction with the retromer complex, resulting in impaired protein recycling and increased amyloidogenic APP processing. SORL1’s pathogenicity is relevant in both early- and late-onset forms of AD, and its deficiency is a proposed upstream trigger for sporadic Alzheimer’s disease development[1][2][3]. SORL1 is studied as a potential therapeutic target for AD, mainly through strategies that enhance retromer-mediated recycling to shift APP processing away from amyloid beta peptide generation.
Enhancement of retromer function to promote non-amyloidogenic APP recycling; Stabilization of endosomal recycling to decrease amyloidogenic processing
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sortilin-related receptor 1 (SORL1).